Compare Recursion Pharmaceuticals Inc (RXRX) vs Ulta Beauty Inc (ULTA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Recursion Pharmaceuticals Inc vs Ulta Beauty Inc — how do they compare? Recursion Pharmaceuticals Inc trades at $3.29 (market cap $1.81B), while Ulta Beauty Inc trades at $538.05 (market cap $23.27B). The key difference: Ulta Beauty Inc is far larger — about 12.9× Recursion Pharmaceuticals Inc's market cap, and Ulta Beauty Inc is trading nearer its 52-week high, Recursion Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| RXRX | ULTA | |
|---|---|---|
Market Cap | $1.81B | $23.27B |
Sector | Health | Consumer Cyclical |
52-Week High | $6.79 | $706.82 |
52-Week Low | $2.84 | $450.75 |
Enterprise Value | $1.33B | $25.35B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RXRX trades at $3.33, up 1.22% in the last session, with a bearish technical signal and RSI near overbought levels. The company reported a Q2 2026 earnings miss with revenue of $54M and a net loss of $519M, reflecting a net margin of -961.97%. Recent news highlights participation in investor conferences and a Genentech partnership advancement, but competitive pressures and slow revenue growth remain concerns.
Outlook is cautious due to persistent losses and high cash burn, though partnerships provide some validation. Risks include execution challenges in drug discovery and reliance on milestone payments. Analysts show a mixed stance with 40% buy ratings, but the stock faces headwinds from weak profitability and bearish technical trends.
ULTA Beauty trades at $548.66, down 2.92% on the day, with strong technical momentum indicated by bullish moving averages and key support at $542. Fundamentally, the company maintains robust profitability with 39.33% gross margins and 47.45% ROE, though recent earnings showed mixed results with a Q4 miss. Revenue growth has been consistent, reaching $11.3B in 2025, while analyst sentiment remains positive with 56.53% buy ratings.
The outlook for ULTA remains favorable with a consensus price target of $618.29 offering 12.7% upside potential. Key opportunities include omnichannel expansion and digital growth initiatives, while risks involve margin pressure from rising costs and competitive retail landscape. Institutional ownership trends show continued confidence with recent position increases by major funds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →About Ulta Beauty Inc
With more than 1,300 stores and a partnership with Target, Ulta Beauty is the largest specialized beauty retailer in the U.S. The firm offers makeup (43% of 2021 sales), fragrances, skin care, and hair care products (20% of 2021 sales), and bath and body items. Ulta offers private-label products and merchandise from more than 500 vendors. It also offers salon services, including hair, makeup, skin, and brow services, in all stores. Most Ulta stores are approximately 10,000 square feet and are in suburban strip centers. Ulta was founded in 1990 and is based in Bolingbrook, Illinois.
Read more on ULTA →
